61 pagesIn the absence of a cure for Alzheimer’s disease (AD), research efforts have been focusedon the early detection and prediction of individuals who may develop the disease based on demographics, cognitive assessments, genetics, and imaging biomarkers. Heterogeneity and the slow progression of the disease are two factors that often challenge the pathology of the disease. In longitudinal studies such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI), missing data can arise due to reasons such as study design, lost to follow-up or subject non-compliance. We wanted to determine the predictability of risk of conversion in subjects over a five-year time horizon. To this end, we separated subjects from ADNI into two groups, namely th...
Objective:To investigate predictors of missing data in a longitudinal study of Alzheimer disease (AD...
Background: Available therapies for Alzheimer's disease (AD) can only alleviate and delay the advanc...
Background: Despite the increasing availability in brain health related data, clinically translatabl...
Patients with Mild Cognitive Impairment (MCI) have an increased risk of Alzheimer’s disease (AD). Ea...
Alzheimer’s disease (AD) is the most common type of degenerative dementia, and the increasing preval...
Patients with Mild Cognitive Impairment (MCI) have an increased risk of Alzheimer’s disease (AD). Ea...
Alzheimer’s disease (AD) is the most common type of degenerative dementia, and the increasing preval...
Mild cognitive impairment is a preclinical stage of Alzheimer's disease (AD). For effective treatmen...
Alzheimer’s Disease (AD) represents the most frequent (60-80%) subtype of dementia and is one kind o...
International audienceThe anticipation of progression of Alzheimer’s disease (AD) is crucial for eva...
Incipient Alzheimer’s Disease (AD) is characterized by a slow onset of clinical symptoms, with patho...
Treball de fi de grau en BiomèdicaTutors: Oscar Camara Rey, Gerard Sanroma GüellAlzheimer’s Disease ...
INTRODUCTION: Developing cross-validated multi-biomarker models for the prediction of the rate of co...
Alzheimer’s disease (AD) is known as one of the major causes of dementia and is characterized by slo...
<div><p>Incipient Alzheimer’s Disease (AD) is characterized by a slow onset of clinical symptoms, wi...
Objective:To investigate predictors of missing data in a longitudinal study of Alzheimer disease (AD...
Background: Available therapies for Alzheimer's disease (AD) can only alleviate and delay the advanc...
Background: Despite the increasing availability in brain health related data, clinically translatabl...
Patients with Mild Cognitive Impairment (MCI) have an increased risk of Alzheimer’s disease (AD). Ea...
Alzheimer’s disease (AD) is the most common type of degenerative dementia, and the increasing preval...
Patients with Mild Cognitive Impairment (MCI) have an increased risk of Alzheimer’s disease (AD). Ea...
Alzheimer’s disease (AD) is the most common type of degenerative dementia, and the increasing preval...
Mild cognitive impairment is a preclinical stage of Alzheimer's disease (AD). For effective treatmen...
Alzheimer’s Disease (AD) represents the most frequent (60-80%) subtype of dementia and is one kind o...
International audienceThe anticipation of progression of Alzheimer’s disease (AD) is crucial for eva...
Incipient Alzheimer’s Disease (AD) is characterized by a slow onset of clinical symptoms, with patho...
Treball de fi de grau en BiomèdicaTutors: Oscar Camara Rey, Gerard Sanroma GüellAlzheimer’s Disease ...
INTRODUCTION: Developing cross-validated multi-biomarker models for the prediction of the rate of co...
Alzheimer’s disease (AD) is known as one of the major causes of dementia and is characterized by slo...
<div><p>Incipient Alzheimer’s Disease (AD) is characterized by a slow onset of clinical symptoms, wi...
Objective:To investigate predictors of missing data in a longitudinal study of Alzheimer disease (AD...
Background: Available therapies for Alzheimer's disease (AD) can only alleviate and delay the advanc...
Background: Despite the increasing availability in brain health related data, clinically translatabl...